Concise Review: Pluripotent Stem Cell-Derived Cardiac Cells, A Promising Cell Source for Therapy of Heart Failure: Where Do We Stand?

Stem Cells

Volumn 34, Issue 1, 2016, Pages 34-43

  Gouadon, Elodie ^a   Moore Morris, Thomas ^b   Smit, Nicoline W ^c   Chatenoud, Lucienne ^d   Coronel, Ruben ^c   Harding, Sian E ^e   Jourdon, Philippe ^a   Lambert, Virginie ^a   Rucker Martin, Catherine ^a   Pucéat, Michel ^b  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d INSTITUT NECKER ENFANTS MALADES   (France)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiac; Cellular therapy; Embryonic stem cells; Pluripotent stem cells; Progenitor cells; Tissue regeneration

Indexed keywords

CELL DIFFERENTIATION; CELL ENGINEERING; CELL METABOLISM; CELL MIGRATION; HEART FAILURE; HEART MUSCLE CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PLURIPOTENT STEM CELL; PRACTICE GUIDELINE; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; ANIMAL; CARDIAC MUSCLE; CYTOLOGY; DISEASE MODEL; PATHOPHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; MYOCARDIUM; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84954403153     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2205     Document Type: Review

References (95)

1. Braunwald E., The war against heart failure: The Lancet lecture. Lancet 2014; 385.
2. De Keulenaer GW, Brutsaert DL., Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation 2011; 123: 1996-2004; discussion 2005.
3. Jessup M, Greenberg B, Mancini D, et al., Calcium upregulation by percutaneous administration of gene therapy in cardiac disease I: Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011; 124: 304-313.
4. Sanganalmath SK, Bolli R., Cell Therapy for heart failure. A comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013; 113: 810-834.
5. de Jong R, Houtgraaf JH, Samiei S, et al., Intracoronary stem cell infusion after acute myocardial infarction: A meta-analysis and update on clinical trials. Circ Cardiovasc Interv 2014; 7: 156-167.
6. Rosen MR, Myerburg RJ, Francis DP, et al., Translating stem cell research to cardiac disease therapies: Pitfalls and prospects for improvement. J Am Coll Cardiol 2014; 64: 922-937.
7. Mummery CL, Zhang J, Ng ES, et al., Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: A methods overview. Circ Res 2012; 111: 344-358.
8. Takahashi K, Tanabe K, Ohnuki M, et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
9. Tachibana M, Amato P, Sparman M, et al., Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 2013; 153: 1228-1238.
10. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al., Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
11. Takahashi K, Yamanaka S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
12. Gafni O, Weinberger L, Mansour AA, et al., Derivation of novel human ground state naive pluripotent stem cells. Nature 2013; 504: 282-286.
13. Johannesson B, Sagi I, Gore A, et al., Comparable frequencies of coding mutations and loss of imprinting in human pluripotent cells derived by nuclear transfer and defined factors. Cell Stem Cell 2014; 15: 634-642.
14. Yu Y, Chang L, Zhao H, et al., Chromosome microduplication in somatic cells decreases the genetic stability of human reprogrammed somatic cells and results in pluripotent stem cells. Sci Rep 2015; 5: 10114.
15. Tapia N, Scholer HR., p53 connects tumorigenesis and reprogramming to pluripotency. J Exp Med 2010; 207: 2045-2048.
16. Li Y, Feng H, Gu H, et al., The p53-PUMA axis suppresses iPSC generation. Nat Commun 2013; 4: 2174.
17. Foldes G, Matsa E, Kriston-Vizi J, et al., Aberrant alpha-adrenergic hypertrophic response in cardiomyocytes from human induced pluripotent cells. Stem Cell Reports 2014; 3: 905-914.
18. Puceat M, Clement O, Lechene P, et al., Neurohormonal control of calcium sensitivity of myofilaments in rat single heart cells. Circ Res 1990; 67: 517-524.
19. Crook JM, Peura TT, Kravets L, et al., The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell 2007; 1: 490-494.
20. Van Vliet P, Wu SM, Zaffran S, et al., Early cardiac development: A view from stem cells to embryos. Cardiovasc Res 2012; 96: 352-362.
21. Blin G, Nury D, Stefanovic S, et al., A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 2010; 120: 1125-1139.
22. Chong JJ, Yang X, Don CW, et al., Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014; 510: 273-277.
23. Anderson ME, Goldhaber J, Houser SR, et al., Embryonic stem cell-derived cardiac myocytes are not ready for human trials. Circ Res 2014; 115: 335-338.
24. Dunwoodie SL., The role of hypoxia in development of the Mammalian embryo. Dev Cell 2009; 17: 755-773.
25. Josowitz R, Lu J, Falce C, et al., Identification and purification of human induced pluripotent stem cell-derived atrial-like cardiomyocytes based on sarcolipin expression. PLoS One 2014; 9: e101316.
26. Bizy A, Guerrero-Serna G, Hu B, et al., Myosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes. Stem Cell Res 2013; 11: 1335-1347.
27. Zhang Q, Jiang J, Han P, et al., Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. Cell Res 2011; 21: 579-587.
28. Neely JR, Morgan HE., Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 1974; 36: 413-459.
29. Folmes CD, Nelson TJ, Martinez-Fernandez A, et al., Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab 2011; 14: 264-271.
30. Folmes CD, Dzeja PP, Nelson TJ, et al., Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell 2012; 11: 596-606.
31. Gaspar JA, Doss MX, Hengstler JG, et al., Unique metabolic features of stem cells, cardiomyocytes, and their progenitors. Circ Res 2014; 114: 1346-1360.
32. Hom JR, Quintanilla RA, Hoffman DL, et al., The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. Dev Cell 2011; 21: 469-478.
33. St John JC, Ramalho-Santos J, Gray HL, et al., The expression of mitochondrial DNA transcription factors during early cardiomyocyte in vitro differentiation from human embryonic stem cells. Cloning Stem Cells 2005; 7: 141-153.
34. Tohyama S, Hattori F, Sano M, et al., Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 2013; 12: 127-137.
35. Rohr S., Arrhythmogenic implications of fibroblast-myocyte interactions. Circ Arrhythm Electrophysiol 2012; 5: 442-452.
36. Yang X, Rodriguez M, Pabon L, et al., Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol 2014; 72: 296-304.
37. Poon E, Keung W, Liang YM, et al., Proteomic analysis of human pluripotent stem cell-derived, fetal and adult ventricular cardiomyocytes reveals pathways crucial for cardiac metabolism and maturation. Circ Cardiovasc Genet 2015; 8: 427-436.
38. Iwaki K, Sukhatme VP, Shubeita HE, et al., Alpha- and beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. fos/jun expression is associated with sarcomere assembly; Egr-1 induction is primarily an alpha 1-mediated response. J Biol Chem 1990; 265: 13809-13817.
39. Kuppusamy KT, Jones DC, Sperber H, et al., Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes. Proc Natl Acad Sci USA 2015; 112: E2785-E2794.
40. Aguado B, Mulyasasmita W, Su J, et al., improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A 2012; 18: 808-815.
41. Ladage D, Turnbull IC, Ishikawa K, et al., Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther 2011; 18: 979-985.
42. Ibrahim M, Navaratnarajah M, Siedlecka U, et al., Mechanical unloading reverses transverse tubule remodelling and normalizes local Ca(2+)-induced Ca(2+)release in a rodent model of heart failure. Eur J Heart Fail 2012; 14: 571-580.
43. Stuckey DJ, Ishii H, Chen QZ, et al., Magnetic resonance imaging evaluation of remodeling by cardiac elastomeric tissue scaffold biomaterials in a rat model of myocardial infarction. Tissue Eng Part A 2010; 16: 3395-3402.
44. Schaaf S, Shibamiya A, Mewe M, et al., Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 2011; 6: e26397.
45. Yildirim Y, Naito H, Didie M, et al., Development of a biological ventricular assist device: Preliminary data from a small animal model. Circulation 2007; 116: I16-23.
46. Zimmermann WH, Melnychenko I, Wasmeier G, et al,: Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 2006; 12: 452-458.
47. Hamdi H, Planat-Benard V, Bel A, et al., Long-term functional benefits of epicardial patches as cell carriers. Cell Transplant 2014; 23: 87-96.
48. Serpooshan V, Zhao M, Metzler SA, et al., The effect of bioengineered acellular collagen patch on cardiac remodeling and ventricular function post myocardial infarction. Biomaterials 2013; 34: 9048-9055.
49. Chachques JC, Grandjean P, Schwartz K, et al., Effect of latissimus dorsi dynamic cardiomyoplasty on ventricular function. Circulation 1988; 78: III203-216.
50. Ye L, Chang YH, Xiong Q, et al., Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell 2014; 15: 750-761.
51. Dilley RJ, Morrison WA., Vascularisation to improve translational potential of tissue engineering systems for cardiac repair. Int J Biochem Cell Biol 2014; 56C: 38-46.
52. Beeres SL, Atsma DE, van der Laarse A, et al., Human adult bone marrow mesenchymal stem cells repair experimental conduction block in rat cardiomyocyte cultures. J Am Coll Cardiol 2005; 46: 1943-1952.
53. Pijnappels DA, Schalij MJ, van Tuyn J, et al., Progressive increase in conduction velocity across human mesenchymal stem cells is mediated by enhanced electrical coupling. Cardiovasc Res 2006; 72: 282-291.
54. Chang MG, Tung L, Sekar RB, et al., Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation 2006; 113: 1832-1841.
55. Heubach JF, Graf EM, Leutheuser J, et al., Electrophysiological properties of human mesenchymal stem cells. J Physiol 2004; 554: 659-672.
56. Valiunas V, Doronin S, Valiuniene L, et al., Human mesenchymal stem cells make cardiac connexins and form functional gap junctions. J Physiol 2004; 555: 617-626.
57. Gnecchi M, Zhang Z, Ni A, et al., Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103: 1204-1219.
58. Wu W, Niklason L, Steinbacher DM., The effect of age on human adipose-derived stem cells. Plast Reconstr Surg 2013; 131: 27-37.
59. Gnecchi M, He H, Liang OD, et al., Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 367-368.
60. Ibrahim AG, Cheng K, Marban E,: Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2014; 2: 606-619.
61. Sahoo S, Losordo DW., Exosomes and cardiac repair after myocardial infarction. Circ Res 2014; 114: 333-344.
62. Khan M, Nickoloff E, Abramova T, et al., Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res 2015; 117: 52-64.
63. Wang X, Huang W, Liu G, et al., Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J Mol Cell Cardiol 2014; 74: 139-150.
64. Pinto JM, Boyden PA,: Electrical remodeling in ischemia and infarction. Cardiovasc Res 1999; 42: 284-297.
65. de Bakker JM, Coronel R, Tasseron S, et al., Ventricular tachycardia in the infarcted, Langendorff-perfused human heart: Role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol 1990; 15: 1594-1607.
66. Vermeulen JT, McGuire MA, Opthof T, et al., Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res 1994; 28: 1547-1554.
67. Zeisberg EM, Tarnavski O, Zeisberg M, et al., Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-961.
68. Moore-Morris T, Guimaraes-Camboa N, Banerjee I, et al., Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J Clin Invest 2014; 124: 2921-2934.
69. Iredale JP, Benyon RC, Pickering J, et al., Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-549.
70. Ubil E, Duan J, Pillai IC, et al., Mesenchymal-endothelial transition contributes to cardiac neovascularization. Nature 2014; 514: 585-590.
71. Okita K, Nagata N, Yamanaka S., Immunogenicity of induced pluripotent stem cells. Circ Res 2011; 109: 720-721.
72. Pearl JI, Lee AS, Leveson-Gower DB, et al., Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011; 8: 309-317.
73. de Almeida PE, Ransohoff JD, Nahid A, et al., Immunogenicity of pluripotent stem cells and their derivatives. Circ Res 2013; 112: 549-561.
74. Swijnenburg RJ, Schrepfer S, Govaert JA, et al., Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci USA 2008; 105: 12991-12996.
75. Calderon D, Planat-Benard V, Bellamy V, et al., Immune response to human embryonic stem cell-derived cardiac progenitors and adipose-derived stromal cells. J Cell Mol Med 2012; 16: 1544-1552.
76. Huber BC, Ransohoff JD, Ransohoff KJ, et al., Costimulation-adhesion blockade is superior to cyclosporine A and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation. Stem Cells 2013; 31: 2354-2363.
77. Lui KO, Howie D, Ng SW, et al., Tolerance induction to human stem cell transplants with extension to their differentiated progeny. Nat Commun 2014; 5: 5629.
78. Szot GL, Yadav M, Lang J, et al., Tolerance induction and reversal of diabetes in mice transplanted with human embryonic-stem-cell-derived pancreatic endoderm. Cell Stem Cell 2015; 16: 148-157.
79. Herold KC, Gitelman SE, Masharani U, et al., A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-1769.
80. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al., Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
81. Goto R, You S, Zaitsu M, et al., Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3(+) CD4(+) graft infiltrating cells. Am J Transplant 2013; 13: 1655-1664.
82. You S, Zuber J, Kuhn C, et al., Induction of allograft tolerance by monoclonal CD3 antibodies: A matter of timing. Am J Transplant 2012; 12: 2909-2919.
83. Robbins PD, Morelli AE,: Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 2014; 14: 195-208.
84. Kawamura M, Miyagawa S, Miki K, et al., Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012; 126: S29-S37.
85. Voelkel NF, Quaife RA, Leinwand LA, et al., Right ventricular function and failure: Report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114: 1883-1891.
86. Vonk-Noordegraaf A, Haddad F, Chin KM, et al., Right heart adaptation to pulmonary arterial hypertension: Physiology and pathobiology. J Am Coll Cardiol 2013; 62: D22-D33.
87. Norozi K, Wessel A, Alpers V, et al., Incidence and risk distribution of heart failure in adolescents and adults with congenital heart disease after cardiac surgery. Am J Cardiol 2006; 97: 1238-1243.
88. Winter MM, Bouma BJ, Groenink M, et al., Latest insights in therapeutic options for systemic right ventricular failure: A comparison with left ventricular failure. Heart 2009; 95: 960-963.
89. Lambert V, Capderou A, Le Bret E, et al., Right ventricular failure secondary to chronic overload in congenital heart disease: An experimental model for therapeutic innovation. J Thorac Cardiovasc Surg 2010; 139: 1197-1204, 1204 e1191.
90. Kozak MF, Redington A, Yoo SJ, et al., Diffuse myocardial fibrosis following tetralogy of Fallot repair: A T1 mapping cardiac magnetic resonance study. Pediatr Radiol 2014; 44: 403-409.
91. Borenstein N, Jian Z, Fromont G, et al., Noncultured cell transplantation in an ovine model of right ventricular preparation. J Thorac Cardiovasc Surg 2005; 129: 1119-1127.
92. Yerebakan C, Sandica E, Prietz S, et al., Autologous umbilical cord blood mononuclear cell transplantation preserves right ventricular function in a novel model of chronic right ventricular volume overload. Cell Transplant 2009; 18: 855-868.
93. Davies B, Elwood NJ, Li S, et al., Human cord blood stem cells enhance neonatal right ventricular function in an ovine model of right ventricular training. Ann Thorac Surg 2010; 89: 585-593, 593 e581-584.
94. Swindle MM, Makin A, Herron AJ, et al., Swine as models in biomedical research and toxicology testing. Vet Pathol 2012; 49: 344-356.
95. Lambert V, Gouadon E, Capderou A, et al., Right ventricular failure secondary to chronic overload in congenital heart diseases: Benefits of cell therapy using human embryonic stem cell-derived cardiac progenitors. J Thorac Cardiovasc Surg 2015; 149: 708-715.